Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

EPRX

Eupraxia Pharmaceuticals Inc

Oct 18 • 11:55AM ET

2.55

Dollar change +0.10
Percentage change 4.08	%

Healthcare • Biotechnology • Canada • NASD

Peers: GILD VRTX AMGN BIIB REGN INCY NBIX EXEL IONS BMRN

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.92	Insider Own	7.48%	Shs Outstand	35.62M	Perf Week	6.25%
Market Cap	90.83M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	32.96M	Perf Month	-7.61%
Income	-20.70M	PEG	-	EPS next Q	-	Inst Own	12.85%	Short Float	0.39%	Perf Quarter	2.00%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	16.32	Perf Half Y	-4.32%
Book/sh	0.42	P/B	6.12	EPS next Y	-	ROA	-85.73%	Short Interest	0.13M	Perf Year	-
Cash/sh	0.65	P/C	3.89	EPS next 5Y	-	ROE	-151.17%	52W Range	2.20 - 5.58	Perf YTD	-38.72%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-8.05%	ROI	-139.24%	52W High	-54.30%	Beta	-
Dividend TTM	-	Quick Ratio	2.11	Sales past 5Y	0.00%	Gross Margin	-	52W Low	15.91%	ATR (14)	0.22
Dividend Ex-Date	-	Current Ratio	2.11	EPS Y/Y TTM	-12.37%	Oper. Margin	0.00%	RSI (14)	51.33	Volatility	12.85% 8.43%
Employees	-	Debt/Eq	0.31	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	0.24%	Payout	-	Rel Volume	0.27	Prev Close	2.45
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	7.88K	Price	2.55
SMA20	0.31%	SMA50	-1.24%	SMA200	-23.84%	Trades		Volume	928	Change	4.08%

Oct-15-24 07:00AM	Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis (PR Newswire)
Oct-10-24 07:00AM	Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024 (PR Newswire)
Oct-02-24 05:01PM	Eupraxia Pharmaceuticals Strengthens Senior Management Team (PR Newswire)
Sep-19-24 05:00PM	Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases (PR Newswire)
Sep-11-24 07:00AM	Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis (PR Newswire)
07:00AM	Loading…
Sep-04-24 07:00AM	Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) -5.77%
Aug-07-24 05:00PM	Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results (PR Newswire) +5.44%
Aug-02-24 07:00AM	Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility (PR Newswire) -10.14%
Jul-08-24 07:00AM	Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo (PR Newswire)
Jul-03-24 05:00PM	Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, 'Exploring the Rapid Rise of Osteoarthritis' on July 9, 2024 (PR Newswire)
Jun-06-24 05:00PM	Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders (PR Newswire)
Jun-05-24 07:00AM	Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024 (PR Newswire)
May-23-24 05:00PM	Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis (PR Newswire)
May-22-24 07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
07:00AM	Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ('EoE') on May 29, 2024 (PR Newswire)
05:00PM	Loading…
May-21-24 05:00PM	Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis (PR Newswire)
May-14-24 07:00AM	Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024 (PR Newswire)
May-08-24 05:03PM	Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
May-02-24 07:00AM	Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board (PR Newswire)
Apr-11-24 07:00AM	Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024 (PR Newswire) -6.34%
Apr-08-24 07:00AM	Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference (PR Newswire)
Apr-05-24 07:00AM	Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today (PR Newswire)

Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. It delivers drugs into body compartments, such as the joint without any of the common issues with body compartment injections, such as systemic exposure. The firm focuses on arthritis, diabetic macular edema, and chronic pain programs. The company was founded by James A. Helliwell and John Salvatore Montalbano on May 12, 2011 and is headquartered in Victoria, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EPRX

Eupraxia Pharmaceuticals Inc

Upgrade your FINVIZ experience